The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1707
July 22, 2024
View Complete Issue         Table of Contents 2019 
Issue 1707
Subscribers: Log in to read full issue.  Not a subscriber?  Subscribe or purchase issue.
In Brief: RSV Vaccine (Arexvy) for Ages 50-59
July 22, 2024 (Issue: 1707)
The recombinant respiratory syncytial virus (RSV) vaccine Arexvy (GSK) has now received FDA approval for use in adults 50-59 years old who are at increased risk for lower respiratory tract disease (LRTD) caused by RSV. It was previously approved...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this issue?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this issue:
Title: Issue 1707
 


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.